Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
NCT01054339
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG:
rAAV1-CB-hAAT
Sponsor
Beacon Therapeutics
Collaborators
[object Object]